Beta-2 Microglobulin
Beta-2 microglobulin (B2M)
Written by Aaron CuhaReviewed Sep 2026
Also known as: B2M, beta2-microglobulin, MHC class I light chain
A blood protein that rises with age and impairs neurogenesis and memory when injected into young mice. In people it is a long-established clinical analyte and is associated with worse cognition; nobody has tried lowering it for ageing.
Overview
Beta-2 microglobulin is the light chain of MHC class I molecules and is present in everyone's blood. A 2015 Nature Medicine paper identified it as a circulating pro-ageing factor: B2M is elevated in the blood of ageing humans and mice and in the hippocampus of aged mice and young heterochronic parabionts. Exogenous B2M injected systemically, or locally into the hippocampus, impaired hippocampal-dependent cognitive function and neurogenesis in young mice. Mice lacking B2M did not show the usual age-related cognitive decline and had enhanced neurogenesis in old age. The effects were partly mitigated in mice with reduced cell-surface MHC class I, implicating that pathway.
A 2023 Cell paper added a molecular mechanism from an unexpected direction. Studying Down syndrome, the authors found blood-borne factors driving synaptic deficits, identified elevated B2M in human Down syndrome plasma, showed that systemic B2M in wild-type mice produced synaptic and memory defects, and that removing B2M genetically or with an antibody counteracted those impairments. Mechanistically B2M antagonises the NMDA receptor by interacting with the GluN1-S2 loop, and blocking that interaction with competitive peptides restored receptor-dependent synaptic function.
The human evidence is observational. A 2025 analysis of 1,267 US adults aged 60 and over in the NHANES 1999 to 2002 dataset found that each one-unit increase in log-transformed B2M was associated with a 5.13 point fall in Digit Symbol Substitution Test score and a 0.04 increase in the Dunedin Pace of Aging methylation measure, with that pace measure mediating 9.0 percent of the association. B2M is also a long-standing clinical molecule in its own right: it is the protein that accumulates in dialysis-related amyloidosis in people with kidney failure.
No trial has tested lowering B2M for ageing or cognition in a human.
Mechanism of action
In mice, systemic or intrahippocampal B2M impairs hippocampal-dependent cognition and neurogenesis, effects partly mitigated by reducing cell-surface MHC class I. The 2023 molecular work identifies B2M as an endogenous NMDA receptor antagonist acting through the GluN1-S2 loop, with competitive peptides restoring receptor-dependent synaptic function. In humans, B2M's established roles are immunological and renal: it is the invariant light chain of MHC class I, it is cleared by the kidney, and it accumulates and forms amyloid fibrils in people on long-term dialysis. The NMDA receptor mechanism has not been demonstrated in a person.
Human evidence
Observational, and reasonably large for this field. B2M rises with age in human blood, and in 1,267 older US adults higher levels were associated with worse cognitive performance and a faster measured pace of ageing. B2M also has a well-established human pathology of its own in kidney failure. No human has received a B2M-lowering intervention for ageing or cognition.
- NHANES analysis (Frontiers in Aging Neuroscience 2025): 1,267 adults aged 60 and over. Each one-unit rise in log-transformed B2M was associated with a 5.13 point lower Digit Symbol Substitution Test score and a 0.04 higher Dunedin Pace of Aging methylation value after full adjustment, with associations stable across subgroups. Cross-sectional, so direction cannot be established.
- B2M is elevated in the blood of ageing humans, reported in the 2015 Nature Medicine paper alongside the mouse work.
- Human plasma proteomics in Down syndrome found B2M elevated, which was the entry point for the 2023 NMDA receptor mechanism paper.
- Established human clinical context: B2M is cleared by the kidney, accumulates in long-term dialysis patients, and deposits as amyloid in dialysis-related amyloidosis. It is also used clinically as a laboratory analyte in renal and haematological medicine.
- No interventional trial of B2M lowering or blockade for ageing or cognition is registered or published.
What this does not tell you: The NHANES association is cross-sectional and cannot separate cause from consequence, and B2M rises with declining kidney function, which itself tracks with worse cognition and with age. Nine percent mediation by a pace-of-ageing measure, with a confidence interval running from 0.1 to 43.2 percent, is a very wide estimate. Nobody has lowered B2M in a person to see what happens, and because B2M is a structural component of every MHC class I molecule, blocking it systemically would have immunological consequences that no study has assessed.
Reading the research record
The mouse evidence for B2M runs in both directions, which is unusual in this literature: adding it impaired cognition and neurogenesis in young animals, and removing it prevented the usual age-related decline in old ones. That is a stronger design than an association study, and it is still mice.
The reason no human programme exists is structural rather than economic. B2M is not an optional circulating signal; it is the invariant light chain of every MHC class I molecule on every nucleated cell. Lowering it systemically means interfering with antigen presentation, which is why the therapeutic proposals in the literature are narrower: an antibody, or the competitive peptides that block the specific NMDA receptor interaction identified in 2023, rather than depleting the protein. None of those has been tested in a person.
One correction is worth recording for readers who trace this literature. The 2023 Cell paper is frequently listed as the B2M ageing paper. It is not: it is a Down syndrome study, and its contribution is the NMDA receptor mechanism. The ageing paper is the 2015 Nature Medicine one.
The evidence, charted
Fig. 1 · evidence composition
1of 4 citations (25%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 4 distinct years, 2015 to 2025, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Approved
CA
Not approved
Approved in 2 of 4, prescription route in 0, not approved in 2. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Key studies & citations
- Animal2015
beta2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis
Mouse, with human measurement. B2M is elevated in the blood of ageing humans and mice and in the hippocampus of aged mice and young heterochronic parabionts. Exogenous B2M injected systemically or into the hippocampus impaired hippocampal-dependent cognition and neurogenesis in young mice, partly mitigated in mice with reduced cell-surface MHC class I. Absence of endogenous B2M abrogated age-related cognitive decline and enhanced neurogenesis in aged mice. NIH funded.
Nature Medicine - Animal2023
beta2-microglobulin functions as an endogenous NMDAR antagonist to impair synaptic function
Mouse, with human plasma proteomics, in Down syndrome rather than in ageing. Parabiosis and plasma infusion showed blood-borne factors drive synaptic deficits in Down syndrome models. B2M was elevated in human Down syndrome plasma; systemic B2M produced synaptic and memory defects in wild-type mice; genetic deletion or an anti-B2M antibody counteracted the impairments. B2M antagonises NMDA receptor function via the GluN1-S2 loop, and competitive peptides restored receptor-dependent function.
Cell - Human2025
beta2-microglobulin and cognitive decline: unraveling the mediating role of the Dunedin Pace of Aging methylation
1,267 US adults aged 60 and over from NHANES 1999 to 2002. After adjusting for all confounders, each one-unit increase in log-transformed B2M was associated with a 5.13 point lower Digit Symbol Substitution Test score (95 percent CI -9.03 to -1.24) and a 0.04 higher Dunedin Pace of Aging methylation value (95 percent CI 0.01 to 0.07). That pace measure mediated 9.0 percent of the association (95 percent CI 0.1 to 43.2 percent). Cross-sectional and observational.
Frontiers in Aging Neuroscience - Review2016
Dialysis-related amyloidosis: challenges and solutions
Human clinical review of dialysis-related amyloidosis, the condition in which beta-2 microglobulin accumulates and deposits as amyloid in people with long-term kidney failure. This is the established human pathology of B2M accumulation, and it is not an ageing study.
International Journal of Nephrology and Renovascular Disease
Frequently asked questions
Does beta-2 microglobulin cause cognitive decline?
In mice the evidence is causal in both directions: injecting it impaired cognition and neurogenesis in young animals, and mice lacking it did not show the usual age-related decline. In humans the evidence is an association: in 1,267 adults over 60, higher B2M was associated with lower Digit Symbol Substitution Test scores. Association in a cross-sectional dataset cannot establish cause.
Can you lower B2M?
Not as a tested treatment. No trial of B2M lowering or blockade for ageing or cognition is registered. Because B2M is a structural part of every MHC class I molecule, depleting it systemically would interfere with immune antigen presentation, which is why the approaches discussed in the literature are targeted antibodies or peptides that block one specific interaction rather than lowering the protein.
Why is B2M measured in hospitals?
For reasons unrelated to ageing. It is cleared by the kidney and accumulates in people with kidney failure, where long-term accumulation causes dialysis-related amyloidosis, and it is used as a laboratory analyte in renal and haematological medicine.